Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
- Status
- CompletedResults posted
- Why it is watched
- non-weight indication: lean_mass, aging
- Who it enrolls
- age 65 Years to 90 Years; BMI ≥27 required; conditions: Aging; Diabetes Mellitus, Type 2; PreDiabetes; Overweight and Obesity
- Interventions
- Semaglutide Injectable Product; Lifestyle Counseling
- Conditions
- Aging; Diabetes Mellitus, Type 2; PreDiabetes; Overweight and Obesity
- Phase and size
- Phase 4 · 20 participants
- Dates
- Start 2023-04-01
Primary completion 2024-05-20 - Sponsor
- The University of Texas Health Science Center at San Antonio (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Lean Body Mass ChangeBaseline to 20 weeks
02Eligibility
Who can take part
Inclusion Criteria: * Older than 65 * Have prediabetes or diabetes * BMI ≥ 27.0 kg/m2 * Living independently (not in assisted living or nursing home) Exclusion Criteria: * Have heart disease * Have liver disease * Smoke
03Change log
Registry changes
No changes recorded since the trial was added.